Technology developed by a team of scientists at Dartmouth, including faculty, postdoctoral researchers, and graduate students, that contributed to the development of COVID-19 vaccines will allow Dartmouth to make major investments into advancing its research and education enterprise.
Creator of breakthrough coronavirus technology will be awarded $100,000 at Dartmouth on May 13.
Morgan Gilman, a fourth-year graduate student in the McLellan Lab at Geisel, is helping lead efforts to understand how a particular type of protein allows deadly viruses—such as Ebola and RSV (respiratory syncytial virus)—to gain entry into host cells, and how antibodies can be developed to neutralize that process.
Thanks to a collaboration between the pharmaceutical company MedImmune and Geisel structural biologist Jason McLellan, PhD, a long-awaited vaccine to protect infants from RSV may soon become a reality. Their findings are featured as this month’s cover story in the journal Science Translational Medicine.
Structural biologist Jason McLellan, PhD, an assistant professor of biochemistry at Geisel, is doing groundbreaking research on viral proteins that is providing new insights into deadly outbreaks such as Ebola and MERS-CoV.
Upcoming EventsThis page may link to PDF files. Use this link to download Adobe Reader if needed.